Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Open label two arms, non randomized Convalescent Plasma treatment to severe and critical pneumonia COVID-19 hospitlaized patients compared to a historical cohort with matched controls.
Description: progression to critical stage
Measure: INCIDENCE OF CRITICAL PNEUMONIA Time: 14 days after convalescent plasma administrationDescription: mortality
Measure: MORTALITY RATE AMONG CRITICAL PNEUMONIA PATIENTS Time: 28 days after convalescent plasma administrationDescription: time to need mechanical ventilation
Measure: INCIDENCE OF MECHANICAL VENTILATION Time: 14 days after convalescent plasma treatmentDescription: time of mechanical ventilation needed
Measure: DAYS OF MECHANICAL VENTILATION Time: 28 days after convalescent plasma treatmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports